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Background: The effects of neoadjuvant hormonal therapy (NHT) on pathological
features and lymphangiogenesis in patients with prostate cancer (PCa) for each pre-
operative risk classification are unclear.
Methods:To clarify the anti-cancer effects ofNHT,we investigated 153 patients (non-
NHT group = 80 and NHT group = 73) who underwent radical prostatectomy (RP) in
Nagasaki University Hospital. Lymph vessel density and area (evaluated by
D2-40-positive vessels), vascular endothelial growth factor (VEGF)-C and VEGF-D
expressions, and biochemical recurrence (BCR)-free survival were compared between
these two groups for each D’Amico risk classification (low = 33, intermediate = 58,
high = 62 patients).
Results: In low-risk PCa patients, the risks of lymph vessel invasion and BCR were
significantly higher in theNHT group than in the non-NHT group (P = 0.040 and 0.022,
respectively). Such significant differencewas not seen in the intermediate- or high-risk
PCa groups. Lymph vessel density of the peri-tumoral and intra-tumoral areas and the
lymph vessel area were significantly higher (P < 0.001) in the NHT group than in the
non-NHT group in low-risk PCa. In regard to the expression of VEGF-C or VEGF-D,
significant difference was not detected in low-risk PCa.
Conclusions: NHT stimulated cancer cell progression and BCR via up-regulation of
lymphangiogenesis-related parameters in patients with low-risk PCa. Although VEGF-
C and VEGF-D expressions were not changed by NHT, lymph vessel density and area
were increased in low-risk PCa patients. We suggest that NHT for patients with low-
risk PCa may have a high risk for BCR after RP.
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1 | INTRODUCTION
Prostate cancer (PCa) is the most common malignancy in men
worldwide.1 Androgen deprivation therapy (ADT) is one of the
standard tools of care for patients with PCa. Neoadjuvant hormonal
therapy (NHT) based on androgen deprivation is administered to
improve the successful rate and prognosis of local therapy, including
radical prostatectomy (RP) and radiotherapy, in patients with PCa.2,3
There is general agreement that positive surgical margin or extra-
prostatic extension in RP specimens in patients with low grade and
stage PCa is relatively rare, and outcome in these patients is favorable.4
Therefore, NHT is usually selected for patients with high-risk PCa, as
well as somewith patients with intermediate-risk PCa. However, some
patients with low-risk PCa have been administered NHT for a variety
of reasons, for example, anxiety due to waiting periods or the patient's
wishes. Unfortunately, the anti-cancer effects of NHT in patients with
low-risk PCa are not fully understood, because such patients are
relatively rare. Similarly, the influences of NHT on pathological
characteristics and cancer-related factors according to risk grade
have not yet been investigated.
Up-regulation of lymphangiogenesis leads to increased risk of
metastasis andworse prognosis in various types of cancer.5,6 Themost
well-known and strongest regulators of cancer-related lymphangio-
genesis are vascular endothelial growth factor (VEGF)-C and
VEGF-D.7,8 The expressions of VEGF-C and VEGF-D in human
prostate cancer tissues were reported to be positively associated with
the metastatic spread of cancer cells.9,10 On the other hand, several
investigators showed that the expressions of VEGF-C and VEGF-D in
an androgen-dependent prostate cancer cell line (LNCaP) were up-
regulated by androgen depletion.11–13 In addition to such in vitro
studies, the possibility that ADT may stimulate lymphangiogenesis has
been reported in human prostate cancer tissues.13 From these facts,
we hypothesized that ADT might stimulate cancer cell dissemination
via up-regulation of lymphangiogenesis in PCa.
In this study, we investigate the differences in pathological
features and biochemical recurrence (BCR) between RP tissues from
PCa patients who received NHT and those who did not receive NHT
according to risk classification. Next, to analyze the detailed anti-
cancer mechanism of NHT, lymphangiogenesis-related parameters
and the expression of VEGF-C and VEGF-D were also compared
between these two groups.
2 | MATERIALS AND METHODS
2.1 | Patients
We investigated 153 tissues (non-NHT group = 80 and NHT
group = 73) from patients who underwent RP in the Nagasaki
University Hospital. To match the clinicopathological features
between the two groups, patients who had clinical or pathological
invasion into the seminal vesicle or surrounding tissues, presence of
metastasis, or a Gleason score (GS) of 10 were excluded. In addition,
we also excluded patients with a short duration of NHT (<3months) or
serum prostate-specific antigen (PSA) levels >90 ng/mL. The study
protocol was approved by the Human Ethics Review Committee of the
Nagasaki University Hospital, and written informed consent was
obtained from each subject. In RP specimens with NHT, necrotic or
degenerated area was not evaluated. NHT consisted of an anti-
androgen agent (n = 2, 2.7%), luteinizing hormone-releasing hormone
(LH-RH) agonists (n = 33, 45.2%), or maximum androgen blockade
(n = 38, 52.1%). The median duration of NHT was 7 months (mean, 8.2
months; interquartile range, IQR: 4-10 months). BCR was defined as
serum PSA levels >0.2 ng/mL, as measured on two or more occasions.
Risk classification was defined according to the D’Amico risk
stratification system.14
2.2 | Lymphangiogenesis-related factors
To evaluate lymphangiogenesis, we measured lymph vessel density
(LVD) and lymph vessel area (LVA) by staining for D2-40-positive
vessels. In addition, the expressions of VEGF-C and VEGF-Dwere also
analyzed. These analyses were performed by immunohistochemical
staining as described previously.13 Briefly, antigen retrieval was
performed at 95°C for 40min in 0.01M sodium citrate buffer (pH
6.0). Sectionswere then immersed in 3% hydrogen peroxide for 30min
to block endogenous peroxidase activity, and then incubated with the
primary antibodies (D2-40: DakoCytomation, Glostrup, Denmark;
VEGF-C: Zymed Laboratories, San Francisco, CA; and VEGF-D: R&D
Systems, Abingdon, UK) at 4°C overnight. The samples were treated
with labeled polymer peroxidase from the EnVision+ Peroxidase kit
(Dako, Carpinteria, CA) for 60min. Negative controls consisted of
adjacent sections from each sample that were processed without the
primary antibody. The positive control for all antibodies was kidney
tissue with renal cell carcinoma.
2.3 | Evaluation of lymphangiogenesis-related factors
VEGF expression was semi-quantitatively analyzed as previously
described.15 To determine LVD and LVA, sections labelled with anti-
D2-40 antibody were examined. For each tumor section, three to five
hot spots in the field of view (ie, with the greatest density of positively
stained vessels) were evaluated. LVD was defined as the number of
positively stained vessels per high-power field. According to a previous
report,5 the terms intra- and peri-tumoral denote within the tumor
mass and within an area of 500 µM from the tumor border,
respectively. Evaluation and measurements were performed by
computer-aided image analysis (WinROOF version 6.4; Mitani, Fukui,
Japan). In similar to pathological features, necrotic or degenerated
tissues were not evaluated for lymphangiogenesis-related factors.
2.4 | Statistical analyses
Results are expressed as mean ± SD. The Student's t-test was applied
to continuous variables and the Mann-Whitney U-test was used for
other data. The χ2 test and Fisher exact test were used for categorical
data comparisons. The Kaplan-Meier survival curve and log-rank test
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along with multivariate analysis using the Cox proportional hazards
model were used to assess patient survival. All statistical analyseswere
performed using the StatView v.5.0 for Windows software (Abacus
Concepts, San Francisco, CA).
3 | RESULTS
3.1 | Pathological features
As shown in Table 1, all pre-operative parameters, such as serum PSA
levels at diagnosis, GS of biopsy specimens, and clinical T stage, were
higher in the NHT group than in the non-NHT group; however, these
differences between the two groups were not significant (Table 1).
With regard to pathological features of the RP specimens, the
frequency of lymph node metastasis in patients was higher in the NHT
group (6.8%) than in the non-NHT group (1.1%); however, the
difference did not reach statistical significance (Table 1; P = 0.075).
Furthermore, no other pathological parameter showed any statistical
difference between the two groups (Table 1).
Relationships between pathological features and NHT in RP
specimens according to D’Amico risk classification are shown in
Table 2. There was no significant difference in pT stage or lymph node
metastasis between the non-NHT and NHT groups across all D’Amico
risk classifications. Similar results were also found for venous invasion
and nerve invasion (Table 2). In the non-NHT group, lymphatic invasion
was more frequent with increasing risk grade (low-risk = 26.3%,
intermediate-risk = 51.6%, high-risk = 70.0%). However, in the NHT
group, the rate of lymphatic invasion in patients with low-risk disease
(64.3%) was higher compared to that in patients with intermediate-
(29.7%) and high-risk disease (46.9%). In addition, in patients with low-
risk prostate cancer, the frequency of lymphatic invasion was
significantly higher in the NHT group (64.3%) than in the non-NHT
group (26.3%; P = 0.029) (Table 2). Although a similar trend was
observed in the intermediate- and high-risk patients, this difference
did not reach statistical significance (P = 0.090 and 0.065,
respectively).
3.2 | Biochemical recurrence
Kaplan-Meier survival curves showed that theBCR-free survival rate in
the NHT group was significantly worse compared to the non-NHT
group in patients with low-risk disease (P = 0.022; Figure 1A). There
was no significant difference between the non-NHT and NHT groups
in patients with intermediate- (P = 0.713; Figure 1B) and high-risk
disease (P = 0.732; Figure 1C). A multivariate analysis model including
D’Amico risk classification and NHT showed that NHT was not an
independent predictive factor for BCR-free survival (hazard ra-
tio = 1.45, 95% confidence interval = 0.85-2.49; P = 0.174).
3.3 | Lymphangiogenesis
Representative images of D2-40-positive lymph vessels in PCa
tissues are shown in Figure 2. In the non-NHT group, nearly all of
the D2-40-positive vessels were relapsed and the intraluminal space
was narrow (Figure 2A). In particular, there were few lymph vessels
with a lumen in the intra-tumoral area of samples from patients in the
non-NHT group. In fact, we could not measure the LVA in the intra-
tumoral area. In contrast, D2-40-positive lymph vessels in tissues from
patients in the NHT group had a wider inner cavity compared to the
non-NHT group (Figure 2B). In addition, freed from pressure by tumor
mass and contained cancer cells were detected in non-NHT group
(Figure 2C). The level of peri-LVD was significantly higher in the NHT
group (10.3 ± 3.1) than in the non-NHT group (7.9 ± 4.0; P < 0.001).
When similar analyses were performed according to D’Amico risk
classification, a significant difference was detected in low-risk patients
(P < 0.001), but not in intermediate- or high-risk patients (P = 0.079 and



















Low: -6 50 (32.7) 28 (35.0) 22 (30.1)
Middle: 7 63 (41.2) 30 (37.5) 33 (45.2)
High: 8- 40 (26.1) 22 (27.5) 18 (24.7)
T stage 0.083
T1 61 (39.9) 38 (47.5) 23 (31.5)
T2 75 (49.0) 36 (45.0) 39 (53.4)
T3 17 (11.1) 6 (7.5) 11 (15.1)
At operation
pT stage 0.274
T2 98 (64.1) 48 (60.0) 50 (68.5)




79 (98.8) 68 (93.2)
N1 6 (3.9) 1 (1.2) 5 (6.8)
Lymphatic invasion 0.284
Negative 79 (51.6) 38 (47.5) 41 (56.2)




53 (66.3) 52 (71.2)
Positive 48 (31.4) 27 (33.8) 21 (28.8)
Neural invasion 0.674
Negative 76 (49.7) 38 (47.5) 38 (52.1)
Positive 77 (50.3) 42 (52.5) 35 (47.9)
NHT, neoadjuvant hormonal therapy; s-PSA, serum prostate-specific
antigen.
aData were showed as mean/SD.
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P = 0.108, respectively) (Figure 3A). In regard to the relationship
between intra-LVD and D’Amico risk classification, a significant
difference was detected in low-risk patients (P < 0.001), but not in
intermediate- or high-risk patients (P = 0.199 and 0.754, respectively)
(Figure 3B). Peri-LVA was significantly higher in the NHT group
(481.8 ± 133.5) than in the non-NHT group (230.3 ± 104.9; P < 0.001),
and this difference was significant across all D’Amico risk classifica-
tions (Figure 3C). However, the degree of difference in peri-LVA
between the non-NHT and NHT groups decreased according to
D’Amico risk classification (Figure 3C).
3.4 | Lymphangiogenesis-related factors
Across all risk groups, the IRS of VEGF-C expression was significantly
higher in the NHT group (2.8 ± 1.3) than in the non-NHT group
(2.3 ± 1.0; P = 0.013). However, in contrast to LVD and LVA, the
difference between the two groups in low-risk patients was not
significant (P = 0.205; Figure 4). As with VEGF-C, there was no
significant difference in VEGF-D expression between the two groups
in low-risk patients (P = 0.108; Figure 4), although the difference was
significant in intermediate- and high-risk patients (P = 0.011 and 0.004,
respectively; data not shown).
4 | DISCUSSION
Several clinical trials have shown that NHT can significantly decrease
the rate of positive surgical margin and the risk of extra-prostatic
disease extension in PCa patients treated with RP.2,16–18 On the other
hand, studies have also shown that NHT has no impact on down-
staging or improvement of outcome in these patients.19 Speculated
reasons for this discrepancy include differences in study population,
pathological backgrounds, and methods of NHT. We also believe that
inclusion of prostate cancer patients with low-risk disease influenced
our results on the anti-cancer effects of NHT, because the clinical
merits of NHT in low-risk disease are guessed to be minimum at best,
and potentially none. However, surprisingly, our results showed that
NHT led to cancer progression and a shortening of the BCR-free
survival period in low-risk PCa patients, but not in intermediate- or
high-risk patients.
TABLE 2 Pathological features in radical surgical specimens according to D’Amico risk classification
Low risk Intermediate risk High risk
Non-NHT, N = 19 NHT, N = 14 Non-NHT, N = 31 NHT, N = 27 Non-NHT, N = 30 NHT, N = 32
pT stage
T2 14 (73.7) 12 (85.7) 20 (64.5) 18 (66.7) 14 (46.7) 20 (62.5)
T3 5 (26.3) 2 (14.3) 11 (35.5) 9 (33.3) 16 (53.3) 12 (37.5)
P-value 0.404 0.864 0.211
pN stage
N0 19 (100) 14 (100) 31 (100) 26 (96.3) 29 (96.7) 28 (87.5)
N1 0 (0) 0 (0) 0 (0) 1 (3.7) 1 (0.3) 4 (12.5)
P-value – 0.280 0.185
Lymphatic invasion
Negative 14 (73.7) 5 (35.7) 15 (48.4) 19 (70.3) 9 (30.0) 17 (53.1)
Positive 5 (26.3) 9 (64.3) 16 (51.6) 8 (29.7) 21 (70.0) 15 (46.9)
P-value 0.029 0.090 0.065
Vascular invasion
Negative 15 (78.9) 10 (71.4) 20 (64.5) 22 (81.5) 18 (60.0) 20 (62.5)
Positive 4 (21.1) 4 (28.6) 11 (35.5) 5 (18.5) 12 (40.0) 12 (27.5)
P-value 0.618 0.149 0.840
Neural invasion
Negative 12 (63.2) 8 (57.1) 12 (38.7) 16 (59.3) 14 (46.7) 14 (43.8)
Positive 7 (36.8) 6 (42.9) 19 (51.3) 11 (40.7) 16 (53.3) 18 (56.2)
P-value 0.727 0.118 0.818
NHT
Anti-androgen – 1 (7.1) – 1 (3.7) – 0 (0.0)
LH-RH agonist – 11 (78.6) – 14 (51.9) – 8 (25.0)
MAB – 2 (14.3) – 12 (44.4) – 24 (75.0)
NHT, neoadjuvant hormonal therapy; LH-RH, luteinizing hormone-releasing hormone; MAB, maximum androgen blockage.
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In order to explain the mechanisms behind these findings, we
investigated lymphangiogenesis-related parameters according to risk
classification. Our results showed that LVA was significantly higher in
the NHT group than in the non-NHT group in all risk classifications.
Intra- and peri-LVD were also significantly different between the non-
NHT group and the NHT group, although only in patients with low-risk
PCa. In short, all lymphangiogenesis-related parameters were higher in
FIGURE 1 Kaplan-Meier survival curves showing biochemical
recurrence-free survival in patients receiving neoadjuvant hormonal
therapy (NHT) versus patients not receiving NHT (non-NHT) in low-
risk prostate cancer (A), intermediate-risk prostate cancer (B) and
high-risk prostate cancer (C)
FIGURE 2 Representative examples of D2-40-positive lymph
vessels in prostate cancer tissue from patients who did not
received neoadjuvant hormonal therapy (non-NHT) (A) and
received NHT (B). As shown in A, most lymph vessels are
relapsed and the intraluminal space is narrow in the non-NHT
sample (Magnification ×200). On the other hand, lymph
vessels in the NHT group had a relatively wide inner cavity
(B: Magnification ×200). In regard to lymph vessel in intra-
tumoral area (allow), intraluminal space in NHT group (B) is
wider compared to that in non-NHT group (A). In addition,
vessels freed from pressure by tumor mass and contained
some cells were found in the NHT specimen (C: magnification
×400)
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RP tissues from the NHT group compared to those from the non-NHT
group in low-risk PCa patients only. Increased LVA and LVD are known
to be positively associated with tumor development and worse
prognosis in patients with PCa.20,21 From these facts, we speculated
that up-regulation of lymphangiogenesis by NHT was one of the
reasons for this association. There is a question as to why increased
LVAwas not associated with progression in patients with intermediate
- and high-risk PCa. Although we did not determine the reason for this
phenomenon in this study, we postulate that themalignant behavior of
prostate cancer cells in high grade and stage disease is regulated by
more varied and stronger cancer-related factors.
Next, we analyzed the detailed mechanisms of lymphangiogenesis
under NHT in tissues from patients with low-risk PCa. At first, we
hypothesized that VEGF-C and/or VEGF-D would be up-regulated by
NHT, because VEGF-C and VEGF-D are strong stimulators of
lymphangiogenesis in PCa,8–10 and their expressions were increased
by androgen deprivation in vivo and in vitro.12,13 However, contrary to
our expectation, there was no significant difference in the expressions
of these factors between the non-NHT group and the NHT group in
patients with low-risk PCa. From these results, we speculated that up-
regulated lymphangiogenesis played a minimal role for such
phenomena in patients with low-risk PCa, although, unfortunately,
we were unable to further pursue this question with our study design.
However, we paid special attention to the pressure from interstitial
fluid and mechanical compression in the intra- and peri-tumoral areas.
In short, several previous reports and this study have shown that lymph
vessels in PCa specimens from patients who did not receive ADT were
small and collapsed compared to those from patients who did receive
ADT, as well as normal prostate tissues.13,20,21 Additionally, pressure
from interstitial fluid and mechanical compression in the intra- and
peri-tumoral areas have been proposed to explain these observa-
tions.22,23 In fact, our finding that LVA was higher in the NHT group
than in the non-NHT group could be explained by the decrease in
pressure and mechanical compression by NHT within and around the
tumor mass. Furthermore, we also speculated that increased LVD in
the NHT group could be explained through a similar mechanism. That
is, extremely occluded lymph vessels within the intra-tumoral area in
the non-NHT group could not be counted as LVD; however,
obstructed lymph vessels by NHT were counted as LVD. Thus, the
anti-cancer effects of NHT create a favorable microenvironment for
lymph vessel invasion and cancer cell dissemination via cancer-related
lymph vessels.
The major limitation of this study was the small sample size.
Another limitation is the inherent potential of bias due to its
FIGURE 3 Peri-tumoral (A) and intra-tumoral (B) lymph vessel
density in prostate cancer patients receiving neoadjuvant
hormonal therapy (NHT) and those not receiving NHT (non-NHT)
in low-, intermediate-, and high-risk prostate cancer. Lymph vessel
area in patients receiving NHT and those not receiving NHT (non-
NHT) in low-, intermediate-, and high-risk prostate cancer (C).
Data are shown as mean (upper row) and standard deviation
(lower row)
FIGURE 4 Vascular endothelial growth factor (VEGF)-C and
VEGF-D expression in low-risk prostate cancer patients receiving
neoadjuvant hormonal therapy (NHT) and those not receiving NHT
(non-NHT). Data are shown as mean (upper row) and SD (lower
row)
MIYATA ET AL. | 1413
retrospective nature. However, the frequency of patientswith low-risk
PCa treated with RP after NHT is relatively rare. In addition, a
prospective randomized trial of patients with low-risk PCa to confirm
the anti-cancer effects of NHT, including changes to cancer-related
factors, is difficult because low-risk PCa patients are usually treated
with local therapy, including RP and radiotherapy, without NHT or
active surveillance. Furthermore, a retrospective multi-center study
would be inadequate for our study design, owing to differences in
pathological diagnosis and methods of RP.
NHT is mainly performed in patients with intermediate- and high-
risk PCa. Therefore, the clinical usefulness of our results might be
limited. However, in addition to RP, NHT has been performed in
patients receiving radiotherapy and cryotherapy.3,24 Furthermore,
ADT administration was selected for patients with high age and severe
complicated diseases in spite of low-risk PCa. Based on these facts, we
believe that the results of this study provide key information in
understanding the pathological changes precipitated by ADT and in
discussing treatment strategies in PCa patients with low-risk disease.
5 | CONCLUSIONS
Our results demonstrated that NHT increased cancer progression and
decreased BCR-free survival via up-regulation of lymphangiogenesis-
related parameters, such as LVD and LVA in patientswith low-risk PCa.
On the other hand, the expressions of VEGF-C andVEGF-D in theNHT
groupwere not different from the non-NHT group. Our results suggest
that NHT for patients with low-risk PCa may increase the risk for BCR
after RP.
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